Previous 10 | Next 10 |
ESSA Pharma Inc. (EPIX) is expected to report $-0.17 for Q1 2024 QuidelOrtho Corp Com (QDEL) is expected to report $2.01 for Q4 2023 FaZe Holdings Inc. (FAZE) is expected to report for Q4 2023 Portsmouth Square, Inc. (PRSI) is expected to report for Q2 2024 Similarweb Ltd. (SMWB) ...
Kintara Therapeutics Announces Initiation of REM-001 Clinical Trial for the Treatment of Cutaneous Metastatic Breast Cancer PR Newswire - 15-patient Open Label Study to Confirm Planned Dose and Optimized Study Design Leading to a Phase 3 Clinical Trial in CMBC Patients - ...
2024-01-17 07:30:25 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips It’s time for a breakdown of the biggest pre-market stock movers for Wednesday morning as we check out all of the latest news today! Moving stocks this morning are a canceled dividen...
Kintara Therapeutics Announces Review of Strategic Alternatives PR Newswire - Ladenburg Thalmann Hired as Financial advisor - SAN DIEGO , Dec. 7, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopha...
2023-12-05 09:14:48 ET More on Kintara Therapeutics Kintara slumps on late-stage setback for tumor candidate Seeking Alpha’s Quant Rating on Kintara Therapeutics Historical earnings data for Kintara Therapeutics For further details see: Kintara The...
Kintara Therapeutics Granted Extension by Nasdaq to Regain Compliance with the Stockholders' Equity Continued Listing Requirement PR Newswire SAN DIEGO , Dec. 5, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a bi...
2023-11-14 01:34:50 ET More on Kintara Therapeutics Kintara slumps on late-stage setback for tumor candidate Seeking Alpha’s Quant Rating on Kintara Therapeutics Historical earnings data for Kintara Therapeutics Financial information for Kintara Therap...
Kintara Therapeutics Announces Fiscal 2024 First Quarter Financial Results and Provides Corporate Update PR Newswire SAN DIEGO , Nov. 13, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company ...
Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...
Kintara Therapeutics Inc. (KTRA) is expected to report for Q1 2024
News, Short Squeeze, Breakout and More Instantly...
Kintara Therapeutics Inc Com Company Name:
KTRA Stock Symbol:
NASDAQ Market:
Kintara Therapeutics Announces Fiscal 2024 Third Quarter Financial Results PR Newswire SAN DIEGO , May 14, 2024 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of n...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
Shares of Aon plc (NYSE:AON) fell sharply during Friday's session after the company reported worse-than-expected quarterly financial results. ...